IMUNON (IMNN) announced the appointment of Stacy Lindborg, Ph.D. as President and Chief Executive Officer, CEO, effective May 13, 2024. Dr. Lindborg has served on IMUNON’s board of directors since 2021. Lindborg joins IMUNON from BrainStorm Cell Therapeutics (BCLI), where she was Executive Vice President and Co-Chief Executive Officer
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMNN:
- IMUNON to Hold First Quarter 2024 Financial Results and Business Update Conference Call on Monday, May 13, 2024
- IMUNON’s IND Application Cleared to Begin Human Testing of IMNN-101
- Imunon’s IND application cleared to begin human testing of IMNN-101
- Imunon reports compliance with Nasdaq listing requirements
- IMUNON Reports Compliance with Nasdaq Listing Requirements